NCT03616028进行中（未招募）不适用
The CONFORMAL Early Feasibility Study An Evaluation of the Safety and Performance of the Conformal Left Atrial Appendage Seal for Left Atrial Appendage Occlusion
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 64
- 试验地点
- 11
- 主要终点
- Freedom from major adverse events:
研究概览
简要总结
An evaluation of the safety and performance of the Conformal Left Atrial Appendage Seal for Left Atrial Appendage Occlusion
详细描述
The Conformal Left Atrial Appendage Seal (CLAAS) Device is a permanent implant designed to occlude the left atrial appendage (LAA) to eliminate blood flow into and clot passage from the LAA.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Device Feasibility
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or non-pregnant female aged ≥18 years
- •Documented non-valvular AF (paroxysmal, persistent, or permanent)
- •High risk of stroke or systemic embolism, defined as CHA2DS2-VASc score of ≥ 2 for men and ≥ 3 for women
- •The patient is recommended for oral anticoagulation therapy (OAC), but has an appropriate rationale to seek a non-pharmacologic alternative to chronic oral anticoagulation
- •The patient deemed appropriate for LAA closure by the Site P.I. and a non-interventional physician using an evidenced-based decision-making tool on oral anticoagulants consistent with standard of care.
- •The patient is willing and able to comply with the protocol-specified medication regimen and follow-up evaluations
- •The patient (or legally authorized representative, (where allowed)) has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent approved by the appropriate Institutional Review Board (IRB) or Ethics Committee (EC)
排除标准
- •Pregnant or nursing patients and those who plan pregnancy in the period up to 1 year following the index procedure. Female patients of childbearing potential must have a negative pregnancy test (per site standard test) within 7 days prior to index procedure.
- •Anatomic conditions that would prevent performance of an LAA occlusion procedure (e.g., prior atrial septal defect [ASD] or patient foramen ovale [PFO] surgical repair or implanted closure device, or obliterated or ligated left atrial appendage)
- •Atrial fibrillation that is defined by a single occurrence or that is transient or reversible (e.g., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures)
- •Patients with a medical condition (other than atrial fibrillation) that mandates chronic oral anticoagulation (e.g., history of unprovoked deep vein thrombosis or pulmonary embolism, or mechanical heart valve)
- •History of bleeding diathesis or coagulopathy, or patients in whom antiplatelet and/or anticoagulant therapy is contraindicated
- •Active infection with bacteremia
- •Documented symptomatic carotid artery disease (>50% diameter stenosis with prior ipsilateral stroke or TIA) or known asymptomatic carotid artery disease (diameter stenosis of >70%)
- •Recent (within 30 days pre-procedure) or planned (within 60 days post-procedure) cardiac or non-cardiac interventional or surgical procedure
- •Recent (within 90 days pre-procedure) stroke or transient ischemic attack.
- •Recent (within 60 days pre-procedure) myocardial infarction
- •Vascular access precluding delivery of implant with catheter-based system
- •Severe heart failure (New York Heart Association Class III or IV)
- •Prior cardiac transplant, history of mitral valve replacement or transcatheter mitral valve intervention, or any mechanical valve implant
- •Renal insufficiency, defined as estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 (by the Modification of Diet in Renal Disease equation), or dialysis at the time of screening
- •Platelet count <75,000 cells/mm3 or >700,000 cells/mm3, or white blood cell count <3,000 cells/mm3
- •Patient has a known allergy, hypersensitivity or contraindication to aspirin, heparin, or device materials (e.g., nickel, titanium, gold) or that would preclude any P2Y12 inhibitor therapy, or the patient has contrast sensitivity that cannot be adequately pre-medicated
- •Current participation in another investigational drug or device study
- •Patient is a prisoner
- •Patient is unable to undergo general anesthesia
- •Known other medical illness or known history of substance abuse that may cause non-compliance with the protocol or protocol-specified medication regimen, confound the data interpretation, or is associated with a life expectancy of less than 2 years
- •Patient has a condition which precludes adequate transesophageal echocardiographic (TEE) assessment
- •Echocardiographic Exclusion Criteria
- •Left atrial appendage anatomy cannot accommodate the CLAAS device per manufacturer IFU
- •Intracardiac thrombus or dense spontaneous echo contrast, as visualized by TEE within 2 days prior to implant
- •Left ventricular ejection fraction (LVEF) <30%
- •Circumferential pericardial effusion >10 mm or symptomatic pericardial effusion, signs or symptoms of acute or chronic pericarditis, or evidence of tamponade physiology
- •Atrial septal defect that warrants closure
- •High risk patent foramen ovale (PFO), defined as an atrial septal aneurysm (exclusion >15 mm or length > 15 mm) or large shunt (early [within 3 beats] or substantial passage of bubbles)
- •Moderate or severe mitral valve stenosis (mitral valve area <1.5 cm2)
- •Complex atheroma with mobile plaque of the aorta
- •Patient has evidence of cardiac tumor
研究组 & 干预措施
Non-valvular AF adults
Experimental
Left atrial appendage closure (LAAC) with the CLAAS device will be performed according to the device Instructions for Use, based on TEE, ICE and angiographic guidance, femoral venous access and inter-atrial septum crossing.
干预措施: left atrial appendage closure (Device)
结局指标
主要结局
Freedom from major adverse events:
时间窗: up to 45 days
Major adverse events defined as: All cause mortality, ischemic stroke, systemic thromboembolism, device or procedure-related adverse events requiring open cardiac surgery or major endovascular intervention.
次要结局
- Closure success(45 days post procedure, 6 months, 12 months)
- Major Adverse Events(1year, 2 years, 3 years, 4 years, 5 years)
研究者
研究点 (11)
Loading locations...
相似试验
Unknown
1 期
Study of Safety and Efficacy of a Left Atrial Appendage OcculderNon-valvular Atrial FibrillationStrokeNCT02937025Ya-Wei Xu154
已完成
早期 1 期
Feasibility and Safety Study of LAmbre Left Atrial Appendage OccluderStrokeAtrial FibrillationNCT01920412Lifetech Scientific (Shenzhen) Co., Ltd.20
已完成
2 期
Safety and Effectiveness of Left Atrial Appendage OcclusionAtrial FibrillationNCT00567515AtriCure, Inc.41
进行中（未招募）
不适用
An Early Feasibility Study Evaluating the Safety and Efficacy of the Laminar Left Atrial Appendage Closure System in Subjects With Non-Valvular Atrial FibrillationNon-valvular Atrial FibrillationNCT05565599Biosense Webster, Inc.58
已完成
不适用
A Trial Evaluating the Safety and Effectiveness of the Laminar Left Atrial Appendage Closure System in Subjects With Non-Valvular Atrial FibrillationAtrial FibrillationNCT05224375Laminar, Inc.29